Thursday, November 13, 2003

OncoLink's daily online reports from the Chemotherapy Foundation Symposium in New York City on November 12-14, 2003. For those users interested in obtaining CME for this program, please enter the CME portion of this course.

OncoLink booth at CFS 2003

Adding Carboplatin to Trastuzumab/Paclitaxel in Her2+ Breast Cancer: An Update Presenter: Nicholas Robert, MD Affiliation: US Oncology Research Network The HER family of oncogenes are prevalent in breast cancers. This has allowed for the development of trastuzumab, a monoclonal antibody against the HER2 oncoprotein. Alone...
Adjuvant Hormonal Therapy in Premenopausal Women Faculty Disclosure: Gini F. Fleming, MDIn this presentation Dr. Fleming discusses the use of triptorelin for the treatment of breast cancer which is an off label use. Presenter: Gini F. Fleming, MD Affiliation: University of Chicago Long-term...
Cox-2 Hormonal Approaches for the Treatment and Prevention of Breast Cancer Faculty Disclosure: Paul E. Goss, MD, PhD In this presentation by Dr. Goss there is discussion of celecoxib for the treatment and prevention of breast cancer which is not approved by the FDA. Presenter: Paul E. Goss, MD, PhD Affiliation: Princess...
Duration of Therapy for Ovarian Cancer: How Long is Enough? Presenter: David R. Spriggs, MD Affiliation: MSKCC New York, NY There are little scientific data available on the optimal duration of chemotherapy in the first-line treatment of ovarian cancer. As can be expected, there is even less information...
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Head and Neck Cancer Faculty Disclosure: Merrill S. Kies, MD In this presentation by Dr. Kies there is discussion of C225 in the treatment of head and neck cancer which has not been approved by the FDA. Presenter: Merrill S. Kies, MD Affiliation: MDACC The...
First-Line Therapy for Ovarian Carcinoma: What Next? Faculty Disclosure: Tate Thigpen, MD This presentation by Dr. Thigpen discusses the use of cetuximab, bevacizumab, and PSC 833 for the treatment of ovarian cancer which has not been approved by the FDA. Also discussed are off label uses of...
Motexafin Gadolinium (MGd) and Concurrent Chemoradiation in Head and Neck Cancer Faculty Disclosure: David M. Brizel, MD In this presentation Dr. Brizel discusses the use of Motexafin Gadolinium (MGd)in the treatment of head and neck cancer which has not been approved by the FDA. Presenter: David M. Brizel, MD Affiliation:...
Paclitaxel and Platinum versus Platinum-based Chemotherapy in Relapsed Ovarian Cancer: ICON 4 Presenter: Jonathan A. Ledermann, MD Affiliation: University College, London, UK/ MRC The optimal second-line chemotherapy for platinum-sensitive patients with relapsed ovarian cancer is an issue of ongoing research. Despite advances in therapy...
Update on Gynecologic Oncology Group Studies in Ovarian Cancer Faculty Disclosure: Robert F. Ozols, MD This presentation by Dr. Ozols discusses the use of bevacizumab (Avastin), Erbitux (C225), and PS 341 for the treatment of ovarian cancer which is not approved by the FDA. Also discussed is the off label use...
Vaccines for Breast Cancer: Real Challenge or Reality? Faculty Disclosure: Nuhad K. Ibrahim, MD This presentation by Dr. Ibrahim discusses the use of the STn vaccine for the treatment of breast cancer which has not been approved by the FDA. Presenter: Nuhad K. Ibrahim, MD Affiliation: M.D. Anderson...